A phase II multicentre double-blind randomised placebo-controlled four-way cross-over dose-range funding study to evaluate efficacy, safety and tolerability of PSD502 in subjects with premature ejaculation (PE).

Trial Profile

A phase II multicentre double-blind randomised placebo-controlled four-way cross-over dose-range funding study to evaluate efficacy, safety and tolerability of PSD502 in subjects with premature ejaculation (PE).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Lidocaine/prilocaine (Primary)
  • Indications Premature ejaculation
  • Focus Therapeutic Use
  • Sponsors Plethora Solutions
  • Most Recent Events

    • 29 Jan 2010 Planned number of patients changed from 40 to 35 as reported by ISRCTN: Current Controlled Trials.
    • 27 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top